Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
about
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dogThe role of late I Na in development of cardiac arrhythmiasIon Channels in the HeartMechanisms of ranolazine's dual protection against atrial and ventricular fibrillationNew treatment options for late Na current, arrhythmias, and diastolic dysfunctionLate Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial FibrillationComputational cardiology: how computer simulations could be used to develop new therapies and advance existing onesProton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazineEHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.American Heart Association atrial fibrillation research summit: a conference report from the American Heart AssociationSuppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazineVoltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo.Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atriaA truncating SCN5A mutation combined with genetic variability causes sick sinus syndrome and early atrial fibrillation.Effect of dronedarone on Na+, Ca2+ and HCN channels.Antiarrhythmic drugs for atrial fibrillation.Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Advances in the Pharmacological Treatment of Atrial Fibrillation.Ranolazine: a new approach to treating an old problem.Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparationsAtrial-selective sodium channel block as a strategy for suppression of atrial fibrillationEffects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart modelMechanism of action of the new anti-ischemia drug ranolazine.Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Comparison of the effects of a transient outward potassium channel activator on currents recorded from atrial and ventricular cardiomyocytesMechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent blockMechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical modelNovel pharmacological targets for the rhythm control management of atrial fibrillation.Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs.Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalolAtrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.Excavatolide B Modulates the Electrophysiological Characteristics and Calcium Homeostasis of Atrial Myocytes.Drug therapy in atrial fibrillation management: where do we stand in 2010?Novel anti-arrhythmic medications in the treatment of atrial fibrillationEfficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis.
P2860
Q24607775-270613BC-B0D7-48B3-8393-62585043CA32Q26823149-A88E4EB9-5454-4D5D-85CD-B87A2DDFD7C0Q26829681-654B6179-8216-42A3-83B5-4C8F938B45FCQ26995558-BD2E02AE-4D49-4C04-8152-CBE1ED1E380AQ27012532-185C0671-AD0C-4B97-98AB-037740274D82Q27303632-D6089FB4-6927-442C-8A2E-BA941D707FC6Q27694521-C45582F8-1097-4808-8E4C-2D2E290A22B7Q28293492-85E24810-0FC0-4400-800A-DA6AD5A27BD8Q30375302-059FC144-846F-4A14-9C3E-A5D89E143E95Q30425918-8279504E-0809-4E36-898E-111DF7EE8939Q30622882-2478EF56-F985-4B32-9C4C-11ADB26AC7CDQ30973910-A5623F9B-DE73-41B7-BC40-0EA9EE593D43Q31136281-634A0810-0F88-4678-9C17-2C9EB387B91FQ33665436-0F6BEB59-E8B8-4CD5-ADE2-AF04B4E8E240Q33752259-25E29F4F-99B5-43DA-AAAD-98463E1642C9Q33807062-C77338B7-5F4F-4C82-97CE-D488E8895B89Q33821199-37DB22C9-1EF7-4067-B958-C3B09295DA5BQ33916951-F558219F-7DB3-46AA-BAB6-FF2E1B3DF05DQ34181734-FB17BF2E-513A-4CFC-BEA5-09F49A3B6CBCQ34383573-F0B4040D-621E-430E-A60E-09CBA909CE23Q34457675-2A6BBD38-2D41-48E0-8FB4-459A84A42640Q34482842-4FD46EB3-D1A9-4BA5-8321-2B35AB82DD94Q34682939-220FB251-E97A-4A62-BD33-9D809B66D40FQ34765700-83183491-1E33-40E3-B86B-159B8317A306Q34853000-98446768-498A-46E9-A390-C54A8B91437CQ34901966-5B5854AF-510D-4390-92CA-AA2FCB713979Q35091243-EC8BFCF8-2A94-415A-AC05-E57EBA71CECCQ35106110-443ADD6E-6320-46A0-A7F8-030EA940A0CBQ35395995-4CC670CF-BAB0-40ED-9403-AF83D62F3537Q35396014-D03889F1-F248-4564-9469-946B3D33B330Q35489060-5ABFF3E3-665A-42B3-A8C1-5ECE6146E2EFQ35650683-4060B961-9CBB-4163-A469-25F29FAF5474Q35785780-69ACA1D1-B29D-428A-A4E3-B6DE4EF270DAQ35835645-B8B2AD41-EA15-4286-83CA-73D673CE06B3Q35897567-DB4042A9-B759-4AEB-9769-684B84E1EEFEQ36013079-AA397D78-3093-430D-B3E5-CC71E837DE17Q36260790-941F45DE-67F6-47E1-8015-A503AD8B0E85Q36305013-73367D5E-4D99-43A4-A8A8-7552CCB39D91Q36382379-910040B2-F508-4298-90CC-56667CB3E26BQ36400016-00A74318-C53C-48A0-9757-13E937E773B9
P2860
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Atrium-selective sodium channe ...... es and the role of ranolazine.
@en
Atrium-selective sodium channe ...... es and the role of ranolazine.
@nl
type
label
Atrium-selective sodium channe ...... es and the role of ranolazine.
@en
Atrium-selective sodium channe ...... es and the role of ranolazine.
@nl
prefLabel
Atrium-selective sodium channe ...... es and the role of ranolazine.
@en
Atrium-selective sodium channe ...... es and the role of ranolazine.
@nl
P2093
P2860
P1433
P1476
Atrium-selective sodium channe ...... es and the role of ranolazine.
@en
P2093
Alexander Burashnikov
Andrew C Zygmunt
José M Di Diego
Luiz Belardinelli
P2860
P304
P356
10.1161/CIRCULATIONAHA.107.704890
P407
P577
2007-09-04T00:00:00Z